# Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis

> **NCT00663052** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 273 (actual)

## Conditions studied

- Plaque Psoriasis
- Psoriasis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00663052
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 273 (ACTUAL)
- **Last updated:** 2012-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00663052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00663052, "Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00663052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*